Bharat Biotech (Hyderabad) announced on 23 October 2026 that it will cut the price of MOSQIVAC, its brand of the RTS,S/AS01 malaria vaccine, by about 40% — from €9.30 to €5.50 per dose from early 2027.
The agreement is executed by UNICEF and financially backed by Gavi, the Vaccine Alliance; an advance payment from the International Finance Facility for Immunisation (IFFIm) helped make the cut possible.
It is projected to save about $50 million for childhood immunisation programmes in 2027-2029, enough to give up to one million more children the full four-dose course.
RTS,S/AS01 was the first malaria vaccine recommended by WHO (2021). GSK developed it with PATH and transferred production to Bharat Biotech under a January 2021 agreement; GSK still supplies the AS01E adjuvant.
| Feature | RTS,S/AS01 (MOSQIVAC) | R21/Matrix-M |
|---|---|---|
| WHO recommendation | October 2021 (first malaria vaccine) | October 2023 (second) |
| Developer | GSK with PATH | University of Oxford |
| Manufacturer for global supply | Bharat Biotech (antigen; GSK supplies AS01E adjuvant) | Serum Institute of India |
| Target parasite | Plasmodium falciparum | Plasmodium falciparum |
| Latest price move | €9.30 → €5.50 per dose (Oct 2026 deal) | about $4 → $2.99 per dose (Nov 2025 deal) |
Public-private partnership that finances vaccines for lower-income countries; financially backs this deal
Procures vaccines for national immunisation programmes; executed the price agreement
Raises money on capital markets against donor pledges to front-load funding for Gavi; its advance payment enabled the cut
Recommended RTS,S/AS01 (2021) and R21/Matrix-M (2023); publishes the World Malaria Report
Indian vaccine maker; took over RTS,S antigen production and licence from GSK under the 2021 product-transfer agreement
Zero indigenous malaria cases by 2027 and a malaria-free India by 2030
Key: Launched 2016 by the Ministry of Health and Family Welfare; implemented through the National Strategic Plan 2023-2027
WHO-led targeted push in the countries carrying most malaria cases
Key: India joined in July 2019 (Chhattisgarh, Jharkhand, Madhya Pradesh, West Bengal); WHO's World Malaria Report 2024 recorded India's exit from the group in 2024
WHO-coordinated pilot of RTS,S begins in Ghana, Kenya and Malawi
GSK, PATH and Bharat Biotech sign the product-transfer agreement for the RTS,S antigen and a licence to the vaccine
WHO recommends RTS,S/AS01 — the world's first malaria vaccine recommendation
WHO recommends a second vaccine, R21/Matrix-M (Oxford / Serum Institute of India)
GSK and Bharat Biotech pledge to bring the RTS,S price below $5 a dose by 2028
Gavi-UNICEF deal cuts R21 price to $2.99 a dose
Bharat Biotech announces MOSQIVAC price cut from €9.30 to €5.50
New price takes effect
GS Paper 2 > Health; GS Paper 3 > Science and Technology (biotechnology, vaccines)
General Awareness > Science (diseases) and Current Affairs
General Awareness > International organisations, Indian companies
Which one of the following statements is not correct?
Answer: Hepatitis B, unlike Hepatitis C, does not have a vaccine.
Recombinant protein malaria vaccine against P. falciparum; first recommended by WHO (2021)
GSK's adjuvant in the vaccine, still supplied by GSK to Bharat Biotech
Finance facility that front-loads donor pledges to Gavi through bond issues
WHO's High Burden to High Impact malaria approach; India exited the group in 2024